Cochrane · systematic review · CD002845
Oral versus intra‐vaginal imidazole and triazole anti‐fungal treatment of uncomplicated vulvovaginal candidiasis (thrush)
Denison, HJ, Worswick, J, Bond, CM, et al. · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
Sexually Transmitted InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
9
current version
GRADE rated
8
No studies
1
Included studies
NR
No studies 1 · 11.1%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 33.3%Moderate 4 · 44.4%High 1 · 11.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Oral versus intra‐vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis
Population: women aged 16 and over with uncomplicated vulvovaginal candidiasis
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Clinical cure (short term: 5 to 15 days) Oral vs intra‐vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis | OR 1.14 [0.91, 1.43] | 13 studies · 1859 participants | Moderate Downgraded: risk of bias |
Clinical cure (long term; 2 to 12 weeks) Oral vs intra‐vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis | OR 1.07 [0.77, 1.5] | 9 studies · 1042 participants | Moderate Downgraded: risk of bias |
Mycological cure (short term; 5 to 15 days) Oral vs intra‐vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis | OR 1.24 [1.03, 1.5] | 19 studies · 3057 participants | Moderate Downgraded: risk of bias |
Mycological cure (long term; 2 to 12 weeks) Oral vs intra‐vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis | OR 1.29 [1.05, 1.6] | 13 studies · 1661 participants | Moderate Downgraded: risk of bias |
Safety (withdrawals due to adverse effects) Oral vs intra‐vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis | no estimate extracted | 23 studies · 4637 participants | High |
Side effects (patient‐reported side effects) Oral vs intra‐vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis | OR 1.04 | 16 studies · 3155 participants | Low Downgraded: risk of bias |
Treatment preference Oral vs intra‐vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis | no estimate extracted | 12 studies · 2206 participants | Low Downgraded: risk of bias |
Time to first relief of symptoms Oral vs intra‐vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis | no estimate extracted | 10 studies · 1910 participants | Low Downgraded: risk of bias |
Costs Oral vs intra‐vaginal antifungal treatment of uncomplicated vulvovaginal candidiasis | no estimate extracted | NR | No studies |